Skip to main content
. 2022 Apr 4;8(2):00639-2021. doi: 10.1183/23120541.00639-2021

FIGURE 4.

FIGURE 4

Changes in the levels of pro-resolving lipid mediators in plasma samples from e-cigarette, or vaping, product use-associated lung injury (EVALI) subjects. Plasma levels of resolvins (RvD1, RvD2 and RvE1), prostaglandin E2 (PGE2), lipoxin B4 (LXB4) and thromboxane B2 (TXB2) in non-users and EVALI subjects were quantitated using ELISA-based assays. n=6 per group. Data are shown as mean±sem. *: p<0.05; **: p<0.01 as per unpaired t-test.